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Abstract
The only available tuberculosis (TB) vaccine, BacillusBackground: 
Calmette-Guérin (BCG), has variable efficacy. New vaccines are therefore
urgently needed. Why BCG fails is incompletely understood, and the tools
used for early assessment of new vaccine candidates do not account for
BCG variability. Taking correlates of risk of TB disease observed in human
studies and back-translating them into mice to create models of BCG
variability should allow novel vaccine candidates to be tested early in
animal models that are more representative of the human populations most
at risk. Furthermore, this could help to elucidate the immunological
mechanisms leading to BCG failure. We have chosen the monocyte to
lymphocyte (ML) ratio as a correlate of risk of TB disease and have
back-translated this into a mouse model.
: Four commercially available, inbred mouse strains were chosen.Methods
We investigated their baseline ML ratio by flow cytometry; extent of
BCG-mediated protection from M  infection byycobacterium tuberculosis
experimental challenge; vaccine-induced interferon gamma (IFNγ)
response by ELISPOT assay; and tissue distribution of BCG by plating
tissue homogenates.
 The ML ratio varied significantly between A/J, DBA/2, C57Bl/6Results:
and 129S2 mice. A/J mice showed the highest BCG-mediated protection
and lowest ML ratio, while 129S2 mice showed the lowest protection and
higher ML ratio. We also found that A/J mice had a lower antigen specific
IFNγ response than 129S2 mice. BCG tissue distribution appeared higher
in A/J mice, although this was not statistically significant.
 These results suggest that the ML ratio has an impact onConclusions:
BCG-mediated protection in mice, in alignment with observations from
clinical studies. A/J and 129S2 mice may therefore be useful models of
BCG vaccine variability for early TB vaccine testing. We speculate that
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 BCG vaccine variability for early TB vaccine testing. We speculate that
failure of BCG to protect from TB disease is linked to poor tissue distribution
in a ML high immune environment.
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            Amendments from Version 1
This version has been revised to address the reviewers' 
comments. We have now included an analysis of the CD11b 
intermediate, CD11c+ cell population in the lung which should 
be enriched in alveolar macrophages (Figure 1E). We have 
also included a discussion about the main genetic differences 
between the mouse strains, and provided some clarification of 
experimental and technical details. 
See referee reports
REVISED
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) 
is the leading cause of death from a single infectious agent. 
Multidrug-resistant TB remains a public health crisis, and only 
one vaccine (the M. bovis-derived Bacillus Calmette-Guérin, 
BCG) is currently licensed for clinical use. To meet the sustain-
able development goal of ending the TB epidemic by 2030, new 
treatments and vaccines are both urgently needed.
BCG efficacy is highly variable1,2. The reasons why BCG protects 
when it does and why it fails when it doesn’t are incompletely 
understood, but are crucial to the successful design and testing 
of new vaccines3. Furthermore, to be able to accurately assess 
vaccine candidates in models where BCG both protects and does 
not protect very early on in the vaccine development pipeline 
would be highly advantageous and de-risk failure in later stage 
clinical trials. There is however a lack of a broad range of tools 
that can collectively predict with some confidence whether a 
vaccine will be protective.
One of the tools for very early testing of TB vaccine candidates 
is a mouse model. However, in order to obtain meaningful infor-
mation, new vaccine candidates should be tested in models that 
are clinically relevant and reflect the breadth and heterogene-
ity of immune environments and varying BCG efficacy found in 
human populations. We propose that this could be achieved 
by back-translating observations from clinical studies, such as 
correlates of risk of TB disease, into animal models.
A number of correlates of risk of TB disease have recently been 
identified, including transcriptomic mRNA signatures in blood, 
T cell activation, and monocyte to lymphocyte (ML) ratio4–8, 
while others are being investigated (reviewed in 9). We have 
chosen the ML ratio to provide proof of principle that correlates 
of risk can be back-translated into the mouse to develop a model 
for vaccine testing that better reflects the populations most at 
risk of BCG failure.
In this study, we show that inbred, commercially available 
mouse strains have differing ML ratios, and that a high ML 
ratio is associated with lower BCG-mediated protection from 
experimental Mtb challenge. We further suggest that lack of 
BCG dissemination and/or persistence in ML high mice impairs 
protection.
Methods
Ethics statement
All animal work was carried out in accordance with the Animals 
(Scientific Procedures) Act 1986 under a license granted by the 
UK Home Office (PPL 70/8043), and approved locally by the 
London School of Hygiene and Tropical Medicine Animal 
Welfare and Ethics Review Body.
Animals and experiment design
The following mouse strains were used for the experiments 
reported here (abbreviated names used throughout the manu-
script are given in brackets): A/JOlaHsd (A/J); DBA/2OlaHsd 
(DBA/2); C57BL/6JOlaHsd (C57Bl/6); 129S2/SvHsd (129S2). 
Female mice were acquired from Envigo UK at 5–7 weeks of 
age. Animals were housed in specific pathogen-free individually 
vented cages with environmental enrichment (play tunnel and 
tapvei block), with 12 hours light / 12 hours dark cycles, at 
temperatures between 19° – 23°C and relative humidity of 
45 – 65%. Mice were fed sterilized diet RM1 and filtered water 
ad libitum, and were allowed to acclimatize for at least 5 days 
before the start of any experimental procedure. Mice were 
allocated to cages as groups of 5 by technical staff not involved 
in experimental procedures or data analysis, and mice of the same 
strain were housed together. Each cage was allocated to a treat-
ment in no particular order, but without formal randomisation. 
Animal welfare was assessed twice every day before and during 
the study.
Two independent experiments with separate primary outcomes 
were carried out to obtain the data described in this report. In 
Experiment 1, 5 naïve mice of each strain (20 mice total) were 
culled by anaesthetic overdose, and cardiac blood, lungs and 
spleens were collected for determination of the ML ratio by 
flow cytometric analysis (see below for details). The primary 
outcome for this experiment was the ML ratio (Figure 1). In 
Experiment 2, parallel groups of mice (n=5 per group) were 
BCG-immunised or left untreated. These were allocated at the 
start of the study to either an immunogenicity group (IFNγ 
response and BCG dissemination; 10 mice per strain; 40 mice 
total; Figure 3 and Figure 4), or an Mtb challenge group 
(bacterial burden in lung; 10 mice per strain; 40 mice 
total; Figure 2). Six weeks after immunisation, mice were 
infected with Mtb or culled for isolation of cells from lung and 
spleen. In all, a total of 100 mice (25 per strain) was used to 
obtain all data presented here.
The study was not blinded.
Vaccination
The BCG Pasteur strain was obtained from Aeras (Rockville, 
MD, USA) as frozen aliquots. These were stored at -80°C until 
needed. BCG was then thawed at room temperature and diluted 
to a final concentration of 2×106 CFU/ml in physiological saline 
solution for irrigation (Baxter Healthcare, Newbury, UK). Each 
animal received a subcutaneous injection of 100 μl BCG 
containing 2×105 CFU BCG (vaccinated groups). BCG dose 
was confirmed by plating of an aliquot of the prepared vaccine 
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Figure 1. The ML ratio differs significantly in four different inbred mouse strains. A Gating strategy for flow cytometric analysis. Cells from 
naïve animals were fixed, stained and data acquired as described in Materials and Methods. Cell debris was gated out by use of a FSC-SSC 
gate, followed by gating on single cells (FSC-H and FSC-W). A sequential gating strategy was then applied to determine the frequency of 
T cells (CD3+), B cells (B220+), neutrophils (CD11b+ Ly6G+), monocytes/macrophages (CD11b+ CD11clow-int, red gate) and CD11bint CD11c+ 
cells (blue gate) as a percentage of single cells. Plots shown are from a sample of a C57Bl/6 spleen. B–D The ML ratio was calculated by 
dividing the percentage of monocytes/macrophages by the sum of the percentages of B and T cells. ML ratio was analysed in blood (B), lung 
(C) and spleen (D) of four different mouse strains. E Percentage of CD11bint CD11c+ cells in the lung of four different mouse strains, likely to 
be enriched in alveolar macrophages. Each symbol represents one animal; box plots represent the median (middle line), 25th to 75th percentile 
(box) and minimum to maximum value (error bars). Data sets are presented in order of decreasing protection. p values were determined using 
ordinary ANOVA with Holm-Sidak test for multiple comparisons. Multiplicity adjusted p values are reported. A p value <0.05 was considered 
statistically significant.
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Figure 2. Protection from Mtb infection varies after BCG vaccination in ML high and low mouse strains. A Mice of each strain were 
immunised s.c. with 2x10e5 CFU BCG Pasteur (open circles) or left untreated (filled circle), and infected i.n. with 30 CFU Mtb Erdmann 
6 weeks later. Bacterial burden in the lungs of all animals was enumerated 7 weeks after challenge. Each symbol represents one animal. 
Bacterial numbers are given as log10 CFU per whole organ. No bacteria were detected in one of the C57Bl/6 samples; this value was set 
to zero. ∆ indicates the difference in bacterial burden between naïve and BCG immunised mice. p values were determined by Kruskal-
Wallis test with Dunn’s post-test for multiple comparisons between naïve groups, and multiplicity adjusted p values are reported. Individual 
Mann-Whitney tests to compare naïve with BCG immunised groups of each mouse strain. p<0.05 was considered statistically significant. Error 
bars represent the median and interquartile range. LoD: limit of detection. B ML ratio in comparison to protection in the lung of ML high and 
low mice. The median ML ratio in lung (red; as in Figure 1) is plotted together with protection expressed as the median % decrease in CFU 
(blue; as in A).
Figure 3. Antigen-specific interferon gamma response varies in splenocytes of ML high and ML low mouse strains. Splenocytes were 
isolated from BCG-immunised or control mice at the time of Mtb challenge (6 weeks after immunisation), and restimulated with PPD. The 
number of IFNγ producing cells were enumerated using an ELISPOT assay (presented as spot forming units [SFU] per 10e6 cells). Non-
specific background measured in unstimulated duplicate wells was removed. Data sets are presented in order of decreasing protection. Each 
symbol represents one animal. p values were determined by using one-way ANOVA and Dunn’s post test for multiple comparisons. Error bars 
represent the median and interquartile range. Multiplicity adjusted p values are reported. p<0.05 was considered statistically significant.
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Figure 4. BCG distribution varies between lung and spleen after vaccination of ML high and ML low mice. Approximately half of each 
lung (A) and spleen (B) was homogenised at the time of Mtb challenge (6 weeks after immunisation) and plated on 7H11 agar plates to 
determine viable BCG bacteria. Total CFU per organ are reported. Data sets are presented in order of decreasing protection. Each symbol 
represents one animal. In some instances, bacteria could not be detected and values were set to zero. p values were determined by 
using Kruskal-Wallis test and Dunn’s post test for multiple comparisons. Error bars represent the median and interquartile range. Multiplicity 
adjusted p values are reported. p<0.05 was considered statistically significant.
suspension on 7H11 agar plates. Colonies were counted after 
12–14 days of incubation at 37°C. Animals were then rested for 
6 weeks before either infection with Mtb, or sacrifice for cell 
isolation.
BCG enumeration in tissues
Approximately half of each spleen and the right-hand side lobes 
of the lungs from mice in the immunogenicity group were used 
to determine the number of viable BCG bacteria in each organ six 
weeks after vaccination. Tissues were removed aseptically in a 
microbiological safety cabinet and placed in sterile 2 ml screwcap 
vials containing 500 μl PBS + 0.05% Tween80 and Precellys 
1.4mm ceramic beads (CK14; Peqlab, Sarisbury Green, UK). 
A Precellys 24 homogeniser (Peqlab) was used to homogenise 
tissues for 15 s at 5000 rpm before plating. Each entire homoge-
nate was plated onto two 7H11 agar plates containing 10% 
OADC supplement (Yorlab, York, UK) and 0.5% glycerol. Colonies 
were counted after 3 weeks of incubation at 37°C.
Infection with M. tuberculosis
Mice were infected intranasally with M. tuberculosis 
Erdman (BEI Resources, Manassas, VA, USA) 6 weeks after 
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BCG immunization and kept in isolators under CL-3 contain-
ment. Frozen aliquots of Mtb Erdman were thawed at room 
temperature, and diluted in saline. Mice were anaesthetized 
by an intraperitoneal injection of a combination of Ketamine 
(50 mg/kg; Ketalar Pfizer Itd, Kent, UK) and Xylazine (10 mg/kg; 
Rompun; Berkshire, UK) in saline. Each animal then received 
50 μl of the inoculum, estimated to contain 30 CFU. The number 
of bacteria in the inoculum was confirmed by plating aliquots on 
7H11 agar plates containing 10 % OADC and 0.5 % glycerol.
Seven weeks after infection, animals were killed by cervical 
dislocation. Lungs and spleens were removed aseptically and 
homogenized by mechanical disruption in sterile PBS, using the 
plunger of a 5 ml syringe and a 100 μm cell strainer. A series 
of 10-fold dilutions of tissue homogenates in PBS with 0.05 % 
Tween 80 were plated onto 7H11 agar plates with 10 % OADC 
supplement and 0.5 % glycerol. Plates were incubated at 37 °C and 
colonies counted after 3 weeks.
Protection is expressed by the percent reduction of median 
CFU/lung in the BCG group compared to the control group for 
each mouse strain.
Flow cytometry
Single cell suspensions from spleens were prepared in 
RPMI-1640 media (Sigma-Aldrich, Dorset, UK) containing 10% 
heat-inactivated FBS (Labtech International Ltd, Uckfield, UK) 
and 2 mM L-Glutamine (Fisher Scientific, Loughborough, UK) 
as soon as possible after sacrifice. Spleens were mechanically 
disrupted by mashing through a 100μm cell strainer using the 
rubber end of the plunger from a 5ml syringe. Lungs were 
collected into RPMI-1640 media without FBS and cut into 
small pieces of approx. 2mm3 before incubation with 0.5mg/ml 
Liberase TL (Sigma-Aldrich) and 10μg/ml DNAse (Sigma- 
Aldrich). The enzyme reaction was stopped by adding an equal 
amount of media containing 10% FBS and the tissue was 
mashed as above to obtain single cells. Cells were fixed and 
red blood cells lysed by adding lyse-fix solution (PhosFlow; 
Becton Dickinson, Oxford, UK). After fixing, cell suspensions 
were made up in PBS + 1% FBS.
Approximately 106 cells were stained with the following 
antibody cocktail in BD Brilliant Stain buffer as per manufac-
turer’s instructions (Becton Dickinson): CD3-APC/Cy7 (clone 
17A2, 1:80), B220-BV510 (clone RA3-6B2, 1:40), Ly6G-
BV711 (clone 1A8, 1:40), CD11b-BV650 (clone M1/70, 1:60), 
CD11c-BV605 (clone N418, 1:40). All antibodies were 
purchased from Biolegend (via Fisher Scientific).
Cells from each tissue from one mouse per strain were used as 
fluorescence minus one (FMO) controls. These were stained with 
the antibody cocktail as described above, but without one of the 
antibodies. This was done for each antibody. FMO controls were 
used to guide gating.
OneComp beads (eBioscience via Fisher Scientific, Lough-
borough, UK) were stained with single antibodies as per 
manufacturer’s instructions and used to calculate compensation 
using the automatic function in FlowJo version 10.4. Compen-
sation matrices were manually checked and adjusted where 
necessary.
Analysis was carried out using FlowJo version 10.4.
The ML ratio was calculated by dividing the percentage of 
monocytes/macrophages (Mono_Mac) (B220- CD3- Ly6G- 
CD11b+ CD11clo-int) relative to single cells by the percentage of 
B cells (B220+) and T cells (CD3+): Mono_Mac (% of single cells) / 
[B cells (% of single cells) + T cells (% of single cells)]
IFN-γ ELISPOT
To quantify IFN-γ secreting antigen-specific splenocytes, single 
cell suspensions were prepared by mechanical disruption of 
the remaining spleen samples from the immunogenicity group 
through a 100μm cell strainer as soon as possible after sacri-
fice. After lysis of red blood cells, single cell suspensions were 
made up in RPMI-1640 media containing 10% heat-inactivated 
FBS and 2 mM L-Glutamine. 96-well microtiter ELISPOT 
plates (MAIPS4510, Millipore, Watford, UK) were coated with 
10 μg/ml rat anti-mouse IFN-γ (clone AN18, Mabtech, Nacka 
Strand, Sweden). Free binding sites were blocked with RMPI-
1640 supplemented with 10% heat-inactivated FBS and 2 mM 
L-Glutamine. 2×105 of total splenocytes were added and incu-
bated in duplicate with PPD (10 μg/ml), supplemented RPMI as a 
negative control, or Phorbol myristate acetate (PMA) (0.1 μg/ml, 
Sigma-Aldrich) and Phytohemagglutinin (PHA) (1 μg/ml, Sigma-
Aldrich) as a positive control. After overnight incubation at 37°C 
in 5% CO2, IFN-γ was detected with 1 μg/ml biotin labelled rat 
anti-mouse antibody (clone R4-6A2, Mabtech) and 1 μg/ml 
alkaline phosphatase-conjugated streptavidin (Mabtech). The 
enzyme reaction was developed with BCIP/NBT substrate 
(5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium) 
(MP Biochemicals, UK) and stopped by washing the plates with 
tap water when individual spots could be visually detected (up to 
5min). ELISPOT plates were analysed using an automatic plate 
reader. IFN-γ-specific cells are expressed as number of spot- 
forming units (SFU) per million spleen cells after non-specific 
background was subtracted using negative control wells.
Statistical analysis
Groups of animals were compared, and a p value of <0.05 was 
considered statistically significant. Statistical analysis was carried 
out using GraphPad Prism version 6. The specific test used for 
each analysis is described in the figure legends.
Results
The ML ratio differs significantly in four inbred mouse strains
Four commercially available inbred mouse strains were chosen 
to investigate the impact of the baseline ML ratio on BCG 
vaccine efficacy. A/J, DBA/2, C57Bl/6 and 129S2 mice were 
selected to represent varying monocyte frequencies and a range of 
BCG-mediated protection based on available data (Jax Phenome 
Database https://phenome.jax.org;10,11). To allow the direct 
comparison of the ML ratio between strains, animals were age 
and sex matched and all samples were processed at the same 
time, stained with aliquots of the same antibody cocktail, and 
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data acquired as a batch. All animals used in this experiment were 
included in the analysis.
We found significant differences between mouse strains in their 
baseline ML ratio in blood, spleen, and lung (Figure 1). Across 
all tissues, A/J mice showed the lowest ML ratio (Figure 1 B–D). 
In spleen and blood, the ML ratio of DBA/2, C57Bl/6 and 
129S2 mice was higher than A/J, but only minor differences 
were found between those three strains (Figure 1 B and D). In 
the lung, differences between all strains were more apparent 
(Figure 1C). 129S2 mice had the highest ML ratio, with DBA/2 
and C57Bl/6 showing intermediate levels. These differences 
in ML ratio were mostly driven by differing frequencies in 
monocytes/macrophages, with minor differences in B and T cell 
frequencies between mouse strains (Figure. S1–S3).
Dataset 1. Flow cytometry raw data
http://dx.doi.org/10.5256/f1000research.14239.d207942
This file contains the data underlying the analysis of the ML ratio 
and cell subsets in blood, spleen, and lung shown in Figure 1, 
Figure 2B, Figure S1, Figure S2, and Figure S3.
To assess the impact of these differences in ML ratio on BCG 
efficacy in our model, we infected mice of all strains with virulent 
Mtb Erdmann.
Mouse strains with varying ML ratios are differentially 
protected from Mtb infection by BCG
Mice of each strain were vaccinated s.c. with BCG, or left 
untreated, and infected with Mtb Erdmann six weeks later. The 
extent of protection by BCG was measured by determining the 
bacterial burden in lung and spleen of vaccinated and control mice 
(Figure 2). All mice were immunised with the same inoculum 
of BCG and infected using the same inoculum of Mtb, so that 
results of the different strains are directly comparable. All 
animals were included in the analysis and no unexpected 
adverse events were observed. No more than 10% weight 
loss was recorded over the duration of the experiment. We found 
varying degrees of protection (Figure 2A). A/J mice were the 
most protected with a difference in median CFU (∆) between 
vaccinated and control groups of 1.41 log10, followed by DBA/2 
(∆0.81 log10) and C57Bl/6 (∆0.54 log10), and 129S2 mice were 
the least protected (∆0.37 log10). Interestingly, the mouse strain 
with the highest ML ratio in the lung showed the lowest protec-
tion (129S2), and the strain with the lowest ML ratio showed the 
highest protection (A/J; Figure 2B). Some differences were 
also observed in the innate susceptibility between strains, most 
notably C57Bl/6 mice were significantly less susceptible than 
DBA/2 (∆1.16 log10 CFU) or A/J mice (∆1.41 log10 CFU). Alveolar 
macrophages play an important role in the defence against 
respiratory pathogens, however they are not included in the gate 
used here to quantify monocytes/macrophages (Figure 2A). 
While we did not include specific markers for this cell 
population, they carry a CD11b intermediate (CD11bint), CD11c+ 
phenotype. We found that the frequency of CD11bint CD11c+ 
cells was significantly higher in C57Bl/6 mice compared to the 
other mouse strains (Figure 2E).
Next, to investigate whether differential BCG-mediated protec-
tion from Mtb infection was associated with a differential immune 
response, we carried out an IFNγ ELISPOT assay.
Dataset 2. Mtb challenge CFU raw data
http://dx.doi.org/10.5256/f1000research.14239.d197118
This files contains the raw data as colony forming units (CFU) of the 
graphs in Figure 2.
A differential antigen-specific IFNγ response is associated 
with differential protection
To assess the immune response to mycobacterial antigens in the 
differentially protected mouse strains, splenocytes from mice 
vaccinated with BCG were stimulated with PPD, and the number 
of IFNγ-producing cells was measured by ELISPOT (Figure 3). 
IFNγ is a cytokine associated with control of infection in mice12 
and reduced risk of TB disease in humans6. We found that 
there were significantly more antigen-specific IFNγ produc-
ing splenocytes in 129S2 mice than in A/J or DBA/2 mice, both 
of which were better protected by BCG from Mtb challenge than 
129S2 mice.
Since BCG is a live mycobacterium, and monocytes and 
macrophages are the natural host cells for these organisms, it 
was plausible that a high ML ratio and high IFNγ production in 
129S2 mice impair BCG survival and dissemination to and/or 
persistence in tissues, and thus prevent the formation of a 
protective immune response in the lung.
Dataset 3. ELISPOT raw data
http://dx.doi.org/10.5256/f1000research.14239.d197136
This file contains the raw data for the graph shown in Figure 3
BCG dissemination to lung and spleen is impaired in ML 
high mice
To determine the extent to which BCG is found in lungs and 
spleens after s.c. administration, we plated organ homoge-
nates onto 7H11 agar plates and enumerated viable BCG after 
3 weeks of culture (Figure 4). We generally found low numbers 
of bacteria per organ, especially in the lung, where the bac-
terial count did not exceed 80 CFU/lung in any sample. 
Moderate differences were detected between mouse strains. 
Most notably, the most protected ML low A/J mice had the 
highest number of BCG in the lung, while no BCG was detectable 
in the lung of the least protected ML high 129S2 mice.
These data led us to speculate that certain host immune- 
environments, such as a high ML ratio, can influence BCG 
dissemination and/or persistence, which in turn could impact 
BCG efficacy.
The data presented here are from one experiment as detailed in 
the Methods section. To ensure reproducibility, we have endeav-
oured to include as much experimental detail as possible to allow 
others to repeat the study and confirm the results. Groups of ani-
mals of all strains received the same treatments at the same time to 
Page 8 of 18
F1000Research 2018, 7:296 Last updated: 23 AUG 2019
minimise technical variation. We are therefore confident that the 
major differences between strains are true biological differences.
Dataset 4. BCG distribution raw data
http://dx.doi.org/10.5256/f1000research.14239.d197137
This file contains the raw data as colony forming units (CFU) for the 
graph shown in Figure 4.
Discussion
The varying efficacy of BCG has long been a concern for the 
control of the TB epidemic. Numerous factors have been 
discussed as contributors to this, such as population differ-
ences, different BCG strains, vaccination schedules, exposure to 
environmental mycobacteria, co-infections with viruses and/or 
parasites, and geographical location1,3,13–16. While BCG works 
in some populations and protects children from pulmonary and 
extra-pulmonary disease, new vaccines are urgently needed for 
the populations where BCG fails to protect, such as adolescents 
and adults in endemic areas1,2. The incomplete understanding 
of the mechanisms behind BCG failure, together with limited 
tools for early assessment of vaccine efficacy, are hampering the 
development of new vaccines. In order to allow early vaccine 
testing in a model that better represents the populations most at 
risk of TB disease, we have taken a correlate of risk observed in 
human studies and back-translated it into a mouse model. The 
monocyte to lymphocyte (ML) ratio is a non-specific marker 
of inflammation and has been shown to be associated with risk 
of TB disease in several populations, including pregnant HIV 
infected women, people starting anti-retroviral therapy, BCG 
vaccinated infants and latently Mtb infected adolescents7,8,17–19. 
Scriba et al. show a cascade of inflammatory events as ado-
lescents progress towards disease, which appears to start with 
increased Type I/II IFN signalling, followed by an increase in 
monocytes and a decrease in lymphocytes19. An increased risk 
of TB disease in BCG vaccinated individuals with a high ML 
ratio indicates that BCG is failing in those populations.
In order to provide proof of principle that the ML ratio, and 
observations from human studies more generally, can be back- 
translated to develop more clinically relevant mouse models, we 
chose to use commercially available, genetically tractable inbred 
mouse strains. We could show that these have highly varying 
ML ratios in blood, spleen, and lung, and that these differences, 
particularly in the lung, were associated with varying BCG- 
mediated protection from Mtb infection. Using mouse strains 
with genetically different backgrounds means that there are likely 
other confounding factors that could impact vaccine efficacy. 
This is exemplified by the DBA/2 mice, which are well protected 
despite having a relatively high ML ratio across all tissues. 
This could be due to the fact that they have a higher neutrophil 
frequency than some of the other strains (data not shown). 
Although confounding factors may be at play here, this would 
also be the case in a clinical setting since an altered ML ratio can 
have different underlying causes. An increased ML ratio is an 
indicator for inflammation, likely driven by monocytosis during 
inflammation. Some factors that are thought to influence BCG 
efficacy also drive inflammation, such as co-infection with 
viruses or parasites, malnutrition, or exposure to environmental 
mycobacteria. However, as manipulation of ML ratio in vitro 
impacts on ability to control mycobacterial growth, it is likely 
that ML ratio itself is contributing to TB risk, independent of the 
factor driving inflammation20. It is also possible that host genetic 
factors determine baseline inflammation and ML ratio21. If this is 
the case in TB endemic populations, inbred mouse strains with 
naturally varying ML ratios may be a useful model for BCG 
vaccine variability.
There are genetic differences between the inbred mouse strains 
used in this study, some of which have been well described, 
while others are likely to be unknown. Among the most well 
described genetic factors is the mutation of the interleukin-3 
(IL-3) receptor alpha subunit gene in A/J mice, which leads to 
impaired IL-3 signalling and reduced proliferation of haematopoi-
etic stem cells and their differentiation into myeloid precursors. 
This is likely to play a role in the low ML ratio observed in these 
mice22,23. A/J mice additionally carry a defect in the gene for 
Naip5, an intracellular pattern recognition receptor involved in 
control of proliferation of intracellular pathogens24,25. It may 
thus have an effect on BCG persistence and dissemination. 
C57Bl/6 mice carry a polymorphism in the slc11a1 (formerly 
nramp1) gene, which has been shown to determine susceptibil-
ity or resistance to intravenous infection with BCG as defined 
by BCG load in the spleen26. It does not seem to determine sus-
ceptibility to primary Mtb infection in mice, and the effect on 
BCG efficacy is not well studied27. In addition, different inbred 
mouse strains carry different MHC haplotypes. For the strains 
used in this study, they are as follows: 129S2, H2b; C57Bl/6, H2b; 
A/J, H2a; DBA/2, H2d. Each one confers the ability to recognise 
a slightly different range of epitopes, although there is overlap. 
This may also impact BCG- mediated immunity.
It is currently unclear what the relative contributions are of 
genetic and environmental factors to a change in ML ratio21. 
Does a naturally high ML ratio in an individual make them more 
prone to TB disease, or do other factors including Mtb itself drive 
up the ML ratio, causing BCG to fail? Does a naturally high 
ML ratio in an individual exacerbate an inflammatory response 
initiated by environmental factors? There is striking heterogeneity 
in the immune response to BCG in infants vaccinated at 
birth, including in the ML ratio and cytokine responses17. This 
points towards an involvement of host factors, as the influence 
of environmental factors would be limited so early in life. On the 
other hand, Scriba et al. observe increases in inflammation and 
ML ratio over time in adolescents as an individual progresses 
towards active TB disease and diagnosis19. This may point 
towards the pathogen itself as the cause of an altered immune 
environment.
Interestingly, we found a higher number of antigen-specific 
IFNγ-producing splenocytes in unprotected 129S2 mice compared 
to protected A/J mice at the time of Mtb challenge. This 
seemed counterintuitive at first, but is in line with recent 
findings showing that a sub-population of BCG-vacci-
nated infants with an increased ML ratio showed increased 
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T cell-mediated cytokine production, and this was associated 
with increased risk of TB disease17. High monocyte count and 
pro-inflammatory cytokines are indicators for inflammation. It is 
possible that BCG efficacy is impaired in inflammatory immune 
environments, which may be caused by a variety of factors, 
such as chronic viral infection, age, malnutrition, or prolonged 
contact with environmental mycobacteria, all factors thought 
to impact BCG efficacy. Ultimately, BCG is administered into 
host immune environments with a heterogeneity that is not fully 
characterised or understood, yet may have implications for its 
efficacy.
The exact mechanisms behind an altered BCG vaccine efficacy 
in a ML high immune environment are currently unknown. Our 
data indicate that impaired dissemination and/or persistence of 
BCG may play a role in initiating an effective local immune 
response. A study by Kaveh and colleagues has shown that 
BCG persists for up to 16 months in lymph nodes and spleen 
of Balb/c mice and that persistence of live bacilli contributes 
to optimal protection from M. bovis challenge28. Direct inves-
tigation of this phenomenon in humans is not possible; there 
are however reports that indicate that BCG can disseminate 
and persist for years in a variety of organs in humans29,30. It is 
therefore plausible that an immune environment that impairs 
survival of BCG also impairs vaccine efficacy, although we did 
not determine in this study whether the absence of live bacilli in 
lungs of 129S2 mice is due to lack of dissemination or lack of 
persistence.
The absolute numbers of BCG might be under-estimated in this 
study as we only enumerated bacilli that were readily growing 
on standard 7H11 agar plates. Use of PCR methods or culture 
with resuscitation promoting factors may increase yield and 
allow for detection of dormant bacilli and their contribution to 
protection31,32.
If impaired dissemination and/or persistence in certain immune 
environments is indeed reducing BCG vaccine efficacy, it is 
reasonable to assume that other live mycobacterial vaccines 
would have similar limitations. Variability in the ML ratio and 
more general heterogeneity in the host immune environment 
should thus be taken into account when designing new live TB 
vaccines or vaccines based on boosting BCG.
To circumvent potentially impaired dissemination of parenter-
ally administered live vaccines, mucosal administration of live 
vaccines could be considered. Recent evidence shows that 
mucosal administration of BCG confers increased protection in 
animal models, for example by inducing homing of T cells 
into protected mucosal niches33–35. This agrees with the 
notion that BCG needs to be present in the lungs to initiate a 
protective immune response in this organ. Furthermore, subunit 
vaccines should not show decreased efficacy in ML high 
immune environments if our hypothesis is correct. Both these 
possibilities will need careful investigation to shed light on the 
mechanisms behind BCG failure.
We did not investigate the phenotype of monocytes/macro-
phages or T cells in this study, although it is likely that this plays 
a role. In particular, inflammatory monocytes might lead to 
killing of BCG. It will be interesting in future to investigate this, 
as well as comparing the ML ratio and immune cell phenotypes 
before and after BCG vaccination in the different mouse strains 
and locations.
We found a significantly higher proportion of CD11bint CD11c+ 
cells in the lungs of C57Bl/6 mice, which are likely to be enriched 
in alveolar macrophages. Interestingly, C57Bl/6 mice are also 
the strain least susceptible to Mtb infection without BCG vacci-
nation. While the frequency of this population does not seem to 
be associated with BCG-mediated protection after subcutaneous 
administration of the vaccine, it could play a role after intrana-
sal vaccination. Alveolar macrophages are located on the lumi-
nal side of the epithelium, therefore encountering antigens and 
pathogens taken up from environmental air. The monocyte/macro-
phage population included in our ML ratio on the other hand is 
likely to be of interstitial nature, residing on the basal side of the 
epithelium and encountering antigens from the blood stream.
While our data on the susceptibility of naïve mouse strains to 
Mtb infection agrees with other studies36, we found some 
discrepancies between the data presented here and previously 
published data on BCG-mediated protection. A study using 
DBA/2 mice has shown that these mice are not protected by s.c. 
administration of BCG, but control infection with Mtb better 
when vaccinated i.n.11 This is in contrast to our finding that 
DBA/2 mice are protected from Mtb challenge after s.c. vaccina-
tion. However, there are some differences between these two stud-
ies that may explain the different findings: a different source of 
mice was used; protection was assessed at 8 weeks vs 6 weeks 
after vaccination; the BCG strain and Mtb strain differed; and 
the Mtb dose used for challenge was three times higher in the 
study by Aguilo and colleagues compared to ours. Another report 
detailing the susceptibility of different mouse strains to Mtb 
challenge shows that A/J mice are notably less protected than 
C57Bl/6 mice10, while in our hands the opposite is the case. There 
are important differences between the two studies, including 
the age and sex of mice used, the time point after vaccination at 
which protection was measured, and the use of different BCG 
and Mtb strains. In combination, these factors may lead to a dif-
fering extent of protection. With particular relevance to this study, 
the immune cell frequency between male and female animals 
differs in A/J mice. For example, dataset Donahue5 on the 
Jackson Laboratory Mouse Phenome Database indicates a higher 
percentage of monocytes in blood for males compared to females, 
while T cells are less frequent in males, leading to a higher ML 
ratio in males37.
In conclusion, the back-translation of a correlate of risk of TB 
disease, the ML ratio, into an animal model is a step forward for 
better tools to study the immune mechanisms behind BCG 
vaccine failure and to test vaccines in a model more relevant 
to populations most at risk. Hopefully other risk factors can 
also be back-translated in the future to obtain a more complete 
picture of vaccine efficacy at very early stages of testing. We 
would encourage the use of more diverse mouse models in TB 
vaccine testing and development to reflect the heterogeneity 
of immune environments found in human populations.
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Data availability
Dataset 1: Flow cytometry raw data – This file contains the 
data underlying the analysis of the ML ratio and cell subsets in 
blood, spleen, and lung shown in Figure 1, Figure 2B, Figure S1, 
Figure S2, and Figure S3. 10.5256/f1000research.14239.d20794238
Dataset 2: Mtb challenge CFU raw data – This files contains 
the raw data as colony forming units (CFU) of the graphs in 
Figure 2. 10.5256/f1000research.14239.d19711839
Dataset 3: ELISPOT raw data – This file contains the raw data 
for the graph shown in Figure 3. 10.5256/f1000research.14239.
d19713640
Dataset 4: BCG distribution raw data – This file contains the 
raw data as colony forming units (CFU) for the graph shown in 
Figure 4. 10.5256/f1000research.14239.d19713741
Supplementary material
Figure S1: The frequency of T cells varies in tissues of ML high and ML low mouse strains. T cell (CD3+) frequencies were deter-
mined in blood (A), lung (B) and spleen (C) of four different mouse strains using the gating strategy described in Figure 2A. The ML ratio 
was calculated using these data. Each symbol represents one animal; box plots represent the median (middle line), 25th to 75th percentile 
(box) and minimum to maximum value (error bars). Data sets are presented in order of decreasing protection. p values were determined 
using ordinary ANOVA with Holm-Sidak test for multiple comparisons. Multiplicity adjusted p values are reported. A p value <0.05 was 
considered statistically significant.
Click here to access the data.
Figure S2: The frequency of B cells varies in tissues of ML high and ML low mouse strains. B cell frequencies (B220+) were deter-
mined in blood (A), lung (B) and spleen (C) of four different mouse strains using the gating strategy described in Figure 2A. The ML ratio 
was calculated using these data. Each symbol represents one animal; box plots represent the median (middle line), 25th to 75th percentile 
(box) and minimum to maximum value (error bars). Data sets are presented in order of decreasing protection. p values were determined 
using ordinary ANOVA with Holm-Sidak test for multiple comparisons. Multiplicity adjusted p values are reported. A p value <0.05 was 
considered statistically significant.
Click here to access the data.
Figure S3: The frequency of monocytes/macrophages varies in tissues of ML high and ML low mouse strains. Monocyte/macrophage 
(CD11b+ CD11clow-int) frequencies were determined in blood (A), lung (B) and spleen (C) of four different mouse strains using the gating 
strategy described in Figure 2A. The ML ratio was calculated using these data. Each symbol represents one animal; box plots represent the 
median (middle line), 25th to 75th percentile (box) and minimum to maximum value (error bars). Data sets are presented in order of decreas-
ing protection. p values were determined using ordinary ANOVA with Holm-Sidak test for multiple comparisons. Multiplicity adjusted 
p values are reported. A p value <0.05 was considered statistically significant.
Click here to access the data.
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 I have only minor comments and suggestions:
 
Regarding introduction and/or discussion, it would be important the authors discuss what are the main
genetic differences between the 4 mouse strains selected for this study.
 
In Figure 4, it is right to state that colonies vary in tissues but only 2 tissues were analysed here so it would
be more appropriate to state "between lung and spleen". Moreover, would it be possible to get the data in
lymph nodes as well? Lymph nodes are critical for the responses to vaccination.
 
The variation in CFU/organ seem to be higher in animals that have high levels of protection in this study
(e.g. A/J mice). Could the authors comment on this? Is it possible to know the ML ratio in the 2 mice
showing high CFU/lung from Fig 4A?
 
Not sure if the authors have the samples available, but it would have been interesting to see the profiles of
Type I/II IFN in tissue at least by qPCR. This information could be of great interest for the tuberculosis
field.
 
The authors should discuss the limitations of a relatively low number of biological experiments in this
work.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 19 Jun 2018
, Department of Immunology and Infection, Keppel Street, UKAndrea Zelmer
Dear Dr Gutierrez
We would like to thank you for taking the time to review our manuscript, and for the thoughtful
feedback provided. We address your individual comments below. 
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 feedback provided. We address your individual comments below. 
 
The work from Zelmer and collaborators is very interesting, timely, well executed and
clearly written. I anticipate a great interest in the tuberculosis vaccine field. I have only
minor comments and suggestions:
 
Regarding introduction and/or discussion, it would be important the authors discuss what
are the main genetic differences between the 4 mouse strainsselected for this study.
 
We have now included a paragraph in the Discussion to address this.
 
In Figure 4, it is right to state that colonies vary in tissues but only 2 tissues were
analysed here so it would be more appropriate to state "between lung and spleen".
Moreover, would it be possible to get the data in lymph nodes as well? Lymph nodes are
critical for the responses to vaccination.
 
We have now specified “lung and spleen” in the legend to Fig. 4 and also in the sub-heading in the
results section. 
It would be very interesting to look at tissue distribution to lymph nodes, and this is a point both
reviewers have brought up. Unfortunately, we do not have the samples available and no additional
funding is available at the moment to repeat this study. Furthermore, we believe it would be difficult
to justify the use of further animals solely for this purpose; however, we will investigate this in future
experiments and thank you for the suggestion.
 
The variation in CFU/organ seem to be higher in animals that have high levels of
protection in this study (e.g. A/J mice). Could the authors comment on this? Is it possible
to know the ML ratio in the 2 mice showing high CFU/lung from Fig 4A?
 
Since a different set of animals was used for flow cytometry and BCG distribution studies (outlined
in the Methods section), it is not possible to directly compare the ML ratio and BCG CFU of
individual animals.
With regards to variation in Fig. 4, we believe this is likely to be a technical effect – we detected
very few bacilli in general, and especially in the lung, we did not detect any bacteria in some
samples from lesser protected animals. This does not mean there are non – it just means that we
were not able to detect them with the method used. As such, it is difficult to interpret the real
variation within those mouse strains.
 
Not sure if the authors have the samples available, but it would have been interesting to
see the profiles of Type I/II IFN in tissue at least by qPCR. This information could be of
great interest for the tuberculosis field.
 
Unfortunately we do not have those samples available. It is an important point, and would indeed
be very relevant. We plan to investigate this in future studies.
 
The authors should discuss the limitations of a relatively low number of biological
experiments in this work.
We have added a comment to this effect at the end of the results section.
 No competing interests were disclosed.Competing Interests:
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© 2018 Aguilo N. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution Licence
work is properly cited.
 Nacho Aguilo
Department of Microbiology, Preventive Medicine, and Public Health, University of Zaragoza, Zaragoza,
Spain
The study by Zelmer   evaluates in different mouse genetic backgrounds whether the ratio ofet al.
monocytes/macrophages vs T lymphocytes could affect BCG-induced protection. This study results are
highly interesting as it evaluates in an animal model data derived from a previous vaccine efficacy trial. In
addition, it highlights a critical question in the field of vaccine evaluation in mice, which is the
genetic heterogeneity among inbred mouse strains. This issue is of particular importance when we are
assessing vaccines which aim to be moved to humans. During the reading of the manuscript I have found
some minor questions that I think should be amended to improve the quality of the study.
1. I think that the gating criteria used to enclose the monocyte/macrophage population (CD11b CD11c
cells) is excluding myeloid populations that could be highly informative for the outcome of the study. This
is particularly important in the case of the lungs, where naïve alveolar macrophages have a phenotype
CD11b CD11c . Alveolar macrophages represent a first-line defense against respiratory pathogens, and
therefore results could be very informative to know which is the status of these cells in the different strains
used. More even if we consider that authors compare directly data from BCG-induced protection with
the ML ratio in the lungs (Figure 2B).
2. I suggest to make the comparison between ML ratio and protection using a linear regression, so
statistical significance of the shown data could be assessed.
3. I find highly interesting the data showing the differences in BCG persistence among the four strains,
more even considering the influence of vaccine persistence in protective efficacy. This result evidences
that live vaccine persistence does not only depends on the vaccine itself, but also on the host, and this is
a question that should be considered in the future to study novel tuberculosis vaccines. My question is
whether the authors could provide some data of BCG persistence in the local draining lymph nodes (in
addition to lungs and spleen), as they are the primary sites of BCG biodistribution following
subcutaneous/intradermal vaccination. 
Is the work clearly and accurately presented and does it cite the current literature?
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Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
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 Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: tuberculosis vaccines immunology
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 19 Jun 2018
, Department of Immunology and Infection, Keppel Street, UKAndrea Zelmer
Dear Dr Aguilo
Thank you for reviewing our manuscript, and for providing timely and helpful comments and
feedback. We discuss your individual points below.
 
The study by Zelmer  evaluates in different mouse genetic backgrounds whether theet al.
ratio of monocytes/macrophages vs T lymphocytes could affect BCG-induced protection.
This study results are highly interesting as it evaluates in an animal model data derived
from a previous vaccine efficacy trial. In addition, it highlights a critical question in the
field of vaccine evaluation in mice, which is the genetic heterogeneity among inbred
mouse strains. This issue is of particular importance when we are assessing vaccines
which aim to be moved to humans. During the reading of the manuscript I have found
some minor questions that I think should be amended to improve the quality of the study.
 
1. I think that the gating criteria used to enclose the monocyte/macrophage population
(CD11b CD11c cells) is excluding myeloid populations that could be highly informative
for the outcome of the study. This is particularly important in the case of the lungs, where
naïve alveolar macrophages have a phenotype CD11b CD11c . Alveolar macrophages
represent a first-line defense against respiratory pathogens, and therefore results could
be very informative to know which is the status of these cells in the different strains used.
More even if we consider that authors compare directly data from BCG-induced protection
with the ML ratio in the lungs (Figure 2B).
 
We have analysed the frequency of CD11b CD11c cells in the lungs of the four different mouse
strains, and have added Fig. 1E, as well as described the data in the Results section and
discussed it in the Discussion. In brief, the frequency of this population is significantly higher in
C57Bl/6 mice, and seems to be associated with susceptibility of naïve mice, but not BCG-mediated
protection.
+ int 
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 protection.
 
2. I suggest to make the comparison between ML ratio and protection using a linear
regression, so statistical significance of the shown data could be assessed.
 
This would indeed be an informative analysis; however, our experimental design does not allow it
here. Since the data shown from flow cytometry and protection studies were acquired from two
different sets of mice (see Methods section), the data are not paired, and it would not be
appropriate to link them in a linear regression.
 
3. I find highly interesting the data showing the differences in BCG persistence among the
four strains, more even considering the influence of vaccine persistence in protective
efficacy. This result evidences that live vaccine persistence does not only depends on the
vaccine itself, but also on the host, and this is a question that should be considered in the
future to study novel tuberculosis vaccines. My question is whether the authors could
provide some data of BCG persistence in the local draining lymph nodes (in addition to
lungs and spleen), as they are the primary sites of BCG biodistribution following
subcutaneous/intradermal vaccination.
 
This is an important point, and was also raised by Dr Gutierrez, the other reviewer. As you will see
from our response to Dr Gutierrez’ comments, we unfortunately do not have the samples available
and no additional funding is available at the moment to repeat this study. Furthermore, we believe it
would be difficult to justify the use of further animals solely for this purpose; however, we are very
interested to investigate the role of BCG distribution in vaccine efficacy in more detail in the future,
and thank you for the suggestion.
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